A phase I trial involving 40 patients with relapsed/refractory HL that the combination of Vorinostat (300 mg/day orally) with sirolimus (4 mg/day orally, n=22) or Everolimus (5-10 mg/day dose escalation, n=18) yielded ORR of 55% and 33%, respectively, with a median progression-free survival (PFS) of 5.8 months, suggesting synergistic efficacy of HDACi combined with mTOR inhibitors (90)
By focusing on these processes, FOXO4-DRI is intended to help remove these damaged or dysfunctional cells from the body, which can otherwise disrupt normal tissue function and contribute to age-related problems
They can be naturally occurring or synthesized in the lab, making them incredibly versatile for applications in medicine, research, and industry
Erythrocyte sedimentation rate (ESR or "sed" rate) or C-reactive protein (CRP) These are common tests used to measure inflammation in the body
Barisic I, Balenovic D, Udovicic M, Bardak D, Strinic D, Vlaini J, et al
5) Phase 3 CagriSema awaits FDA approval 20262027 as first dual-agonist amylin+GLP-1 medication
